Journal
FREE RADICAL BIOLOGY AND MEDICINE
Volume 205, Issue -, Pages 318-331Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.freeradbiomed.2023.06.006
Keywords
Achaete-scute complex homolog 1; Enzalutamide; CAMP responsive element binding protein 1; Ferroptosis; Neurosecretory prostate cancer
Ask authors/readers for more resources
Neuroendocrine prostate cancer (NEPC) is a highly resistant variant of prostate cancer that often develops in castration-resistant prostate cancer. The mechanisms underlying the trans-differentiation from CRPC to NEPC have not been clarified.
Neuroendocrine prostate cancer (NEPC) is a multi-resistant variant of prostate cancer (PCa) that frequently emerges in castration-resistant prostate cancer (CRPC). NEPC is usually associated with tumor aggression, hormone therapy resistance, and poor clinical outcome. However, the mechanisms underlying the trans-differentiation from CRPC to NEPC have not been elucidated. Achaete-scute complex-like 1 (ASCL1) plays a role in neuronal commitment and differentiation and olfactory and autonomic neuron generation. This study revealed that ASCL1 was regulated by the SRY-box transcription factor 2 (SOX2) and highly expressed in NEPC cells, which was closely related to poor prognosis. Moreover, ASCL1 overexpression significantly enhanced CRPC progression to NEPC by resisting ferroptosis. Mechanically, ferroptosis resistance was mediated by CAMPresponsive element binding protein 1 (CREB1) phosphorylation, promoted by substantially upregulated ASCL1 in NEPC cells. In addition, upregulated SOX2 induced PCa cell differentiation into neuroendocrine tumors by mediating their lineage changes. In conclusion, inhibiting the ferroptosis resistance mediated by ASCL1 could provide a new NEPC therapeutic target and increase patient survival.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available